HEADER TRANSFERASE 24-JUN-21 7R7K TITLE STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE DOMAIN IN COMPLEX WITH TITLE 2 (4-[6-AMINO-5-[(1~{R})-1-[5-FLUORO-2-(TRIAZOL-2-YL)PHENYL]ETHOXY]-3- TITLE 3 PYRIDYL]ISOINDOLIN-1-ONE) COMPND MOL_ID: 1; COMPND 2 MOLECULE: ALK TYROSINE KINASE RECEPTOR; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: ANAPLASTIC LYMPHOMA KINASE; COMPND 5 EC: 2.7.10.1; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: ALK; SOURCE 6 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 7108; SOURCE 8 EXPRESSION_SYSTEM_CELL: SF9; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: BACULOVIRUS; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PFASTBAC KEYWDS KINASE, TRANSFERASE EXPDTA X-RAY DIFFRACTION AUTHOR M.MCTIGUE REVDAT 3 18-OCT-23 7R7K 1 REMARK REVDAT 2 10-AUG-22 7R7K 1 JRNL REVDAT 1 29-JUN-22 7R7K 0 JRNL AUTH A.SHIBA-ISHII,T.W.JOHNSON,I.DAGOGO-JACK,M.MINO-KENUDSON, JRNL AUTH 2 T.R.JOHNSON,P.WEI,S.L.WEINRICH,M.A.MCTIGUE,M.A.WALCOTT, JRNL AUTH 3 L.NGUYEN-PHUONG,K.DIONNE,A.ACKER,L.A.KIEDROWSKI,A.DO, JRNL AUTH 4 J.L.PETERSON,J.L.BARTH,B.Y.YEAP,J.F.GAINOR,J.J.LIN,S.YODA, JRNL AUTH 5 A.N.HATA JRNL TITL ANALYSIS OF LORLATINIB ANALOGS REVEALS A ROADMAP FOR JRNL TITL 2 TARGETING DIVERSE COMPOUND RESISTANCE MUTATIONS IN JRNL TITL 3 ALK-POSITIVE LUNG CANCER. JRNL REF NAT CANCER V. 3 710 2022 JRNL REFN ESSN 2662-1347 JRNL PMID 35726063 JRNL DOI 10.1038/S43018-022-00399-6 REMARK 2 REMARK 2 RESOLUTION. 1.83 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : BUSTER 2.11.7 REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER, REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN, REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.83 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 52.72 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 99.2 REMARK 3 NUMBER OF REFLECTIONS : 28074 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.195 REMARK 3 R VALUE (WORKING SET) : 0.194 REMARK 3 FREE R VALUE : 0.221 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 1411 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 1.83 REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 1.84 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 95.42 REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : NULL REMARK 3 BIN R VALUE (WORKING + TEST SET) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.2332 REMARK 3 BIN FREE R VALUE : 0.3036 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : 24 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2272 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 32 REMARK 3 SOLVENT ATOMS : 259 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 27.76 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.66640 REMARK 3 B22 (A**2) : 6.75000 REMARK 3 B33 (A**2) : -7.41640 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.230 REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.146 REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.128 REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.135 REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.122 REMARK 3 REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797 REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.936 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.922 REMARK 3 REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15 REMARK 3 TERM COUNT WEIGHT FUNCTION. REMARK 3 BOND LENGTHS : 2381 ; 2.000 ; HARMONIC REMARK 3 BOND ANGLES : 3243 ; 2.000 ; HARMONIC REMARK 3 TORSION ANGLES : 803 ; 2.000 ; SINUSOIDAL REMARK 3 TRIGONAL CARBON PLANES : NULL ; NULL ; NULL REMARK 3 GENERAL PLANES : 416 ; 5.000 ; HARMONIC REMARK 3 ISOTROPIC THERMAL FACTORS : 2362 ; 10.000 ; HARMONIC REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL REMARK 3 CHIRAL IMPROPER TORSION : 303 ; 5.000 ; SEMIHARMONIC REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL REMARK 3 IDEAL-DIST CONTACT TERM : 2325 ; 4.000 ; SEMIHARMONIC REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 0.91 REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 3.24 REMARK 3 OTHER TORSION ANGLES (DEGREES) : 16.27 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 7R7K COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 25-JUN-21. REMARK 100 THE DEPOSITION ID IS D_1000257752. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 23-JUN-11 REMARK 200 TEMPERATURE (KELVIN) : 87 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.0 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS3 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 28124 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.830 REMARK 200 RESOLUTION RANGE LOW (A) : 52.720 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.4 REMARK 200 DATA REDUNDANCY : 6.500 REMARK 200 R MERGE (I) : 0.05700 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 23.3000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.83 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.93 REMARK 200 COMPLETENESS FOR SHELL (%) : 98.8 REMARK 200 DATA REDUNDANCY IN SHELL : 6.70 REMARK 200 R MERGE FOR SHELL (I) : 0.47000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: 2XP2 REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 41.84 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.11 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: HANGING DROP VAPOR DIFFUSION AT 13 REMARK 280 DEGREES C. EQUAL VOLUMES OF PURIFIED PROTEIN REMARK 280 SOLUTION(APPROXIMATELY 13-15 MG/ML)CONTAINING 0.0011M INHIBITOR REMARK 280 COMPOUND WERE COMBINED WITH A SOLUTION CONTAINING: 0.15M REMARK 280 AMMONIUM SULFATE, 9-10.5% MONOMETHYLETHER PEG5K AND 0.1M MES IN REMARK 280 THE PH RANGE 5.3-6.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE REMARK 280 286K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 25.80100 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 52.71600 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 28.69450 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 52.71600 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 25.80100 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 28.69450 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1085 REMARK 465 ALA A 1086 REMARK 465 HIS A 1087 REMARK 465 HIS A 1088 REMARK 465 HIS A 1089 REMARK 465 HIS A 1090 REMARK 465 HIS A 1091 REMARK 465 HIS A 1092 REMARK 465 ASN A 1093 REMARK 465 GLY A 1125 REMARK 465 ALA A 1126 REMARK 465 PHE A 1127 REMARK 465 SER A 1136 REMARK 465 GLY A 1137 REMARK 465 MET A 1138 REMARK 465 PRO A 1139 REMARK 465 ASN A 1140 REMARK 465 ASP A 1141 REMARK 465 PRO A 1142 REMARK 465 SER A 1143 REMARK 465 ALA A 1280 REMARK 465 SER A 1281 REMARK 465 TYR A 1282 REMARK 465 TYR A 1283 REMARK 465 ARG A 1284 REMARK 465 LYS A 1285 REMARK 465 TYR A 1401 REMARK 465 GLY A 1402 REMARK 465 PRO A 1403 REMARK 465 LEU A 1404 REMARK 465 VAL A 1405 REMARK 465 GLU A 1406 REMARK 465 GLU A 1407 REMARK 465 GLU A 1408 REMARK 465 GLU A 1409 REMARK 465 LYS A 1410 REMARK 465 VAL A 1411 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 LYS A1101 CG CD CE NZ REMARK 470 HIS A1124 CG ND1 CD2 CE1 NE2 REMARK 470 GLN A1217 CG CD OE1 NE2 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ARG A1248 -7.31 78.95 REMARK 500 ASP A1249 49.27 -147.95 REMARK 500 SER A1332 -4.28 77.39 REMARK 500 REMARK 500 REMARK: NULL DBREF 7R7K A 1093 1411 UNP Q9UM73 ALK_HUMAN 1093 1411 SEQADV 7R7K MET A 1085 UNP Q9UM73 EXPRESSION TAG SEQADV 7R7K ALA A 1086 UNP Q9UM73 EXPRESSION TAG SEQADV 7R7K HIS A 1087 UNP Q9UM73 EXPRESSION TAG SEQADV 7R7K HIS A 1088 UNP Q9UM73 EXPRESSION TAG SEQADV 7R7K HIS A 1089 UNP Q9UM73 EXPRESSION TAG SEQADV 7R7K HIS A 1090 UNP Q9UM73 EXPRESSION TAG SEQADV 7R7K HIS A 1091 UNP Q9UM73 EXPRESSION TAG SEQADV 7R7K HIS A 1092 UNP Q9UM73 EXPRESSION TAG SEQRES 1 A 327 MET ALA HIS HIS HIS HIS HIS HIS ASN PRO ASN TYR CYS SEQRES 2 A 327 PHE ALA GLY LYS THR SER SER ILE SER ASP LEU LYS GLU SEQRES 3 A 327 VAL PRO ARG LYS ASN ILE THR LEU ILE ARG GLY LEU GLY SEQRES 4 A 327 HIS GLY ALA PHE GLY GLU VAL TYR GLU GLY GLN VAL SER SEQRES 5 A 327 GLY MET PRO ASN ASP PRO SER PRO LEU GLN VAL ALA VAL SEQRES 6 A 327 LYS THR LEU PRO GLU VAL CYS SER GLU GLN ASP GLU LEU SEQRES 7 A 327 ASP PHE LEU MET GLU ALA LEU ILE ILE SER LYS PHE ASN SEQRES 8 A 327 HIS GLN ASN ILE VAL ARG CYS ILE GLY VAL SER LEU GLN SEQRES 9 A 327 SER LEU PRO ARG PHE ILE LEU LEU GLU LEU MET ALA GLY SEQRES 10 A 327 GLY ASP LEU LYS SER PHE LEU ARG GLU THR ARG PRO ARG SEQRES 11 A 327 PRO SER GLN PRO SER SER LEU ALA MET LEU ASP LEU LEU SEQRES 12 A 327 HIS VAL ALA ARG ASP ILE ALA CYS GLY CYS GLN TYR LEU SEQRES 13 A 327 GLU GLU ASN HIS PHE ILE HIS ARG ASP ILE ALA ALA ARG SEQRES 14 A 327 ASN CYS LEU LEU THR CYS PRO GLY PRO GLY ARG VAL ALA SEQRES 15 A 327 LYS ILE GLY ASP PHE GLY MET ALA ARG ASP ILE TYR ARG SEQRES 16 A 327 ALA SER TYR TYR ARG LYS GLY GLY CYS ALA MET LEU PRO SEQRES 17 A 327 VAL LYS TRP MET PRO PRO GLU ALA PHE MET GLU GLY ILE SEQRES 18 A 327 PHE THR SER LYS THR ASP THR TRP SER PHE GLY VAL LEU SEQRES 19 A 327 LEU TRP GLU ILE PHE SER LEU GLY TYR MET PRO TYR PRO SEQRES 20 A 327 SER LYS SER ASN GLN GLU VAL LEU GLU PHE VAL THR SER SEQRES 21 A 327 GLY GLY ARG MET ASP PRO PRO LYS ASN CYS PRO GLY PRO SEQRES 22 A 327 VAL TYR ARG ILE MET THR GLN CYS TRP GLN HIS GLN PRO SEQRES 23 A 327 GLU ASP ARG PRO ASN PHE ALA ILE ILE LEU GLU ARG ILE SEQRES 24 A 327 GLU TYR CYS THR GLN ASP PRO ASP VAL ILE ASN THR ALA SEQRES 25 A 327 LEU PRO ILE GLU TYR GLY PRO LEU VAL GLU GLU GLU GLU SEQRES 26 A 327 LYS VAL HET 25J A1501 51 HETNAM 25J 4-(6-AMINO-5-{(1R)-1-[5-FLUORO-2-(2H-1,2,3-TRIAZOL-2- HETNAM 2 25J YL)PHENYL]ETHOXY}PYRIDIN-3-YL)-2,3-DIHYDRO-1H- HETNAM 3 25J ISOINDOL-1-ONE FORMUL 2 25J C23 H19 F N6 O2 FORMUL 3 HOH *259(H2 O) HELIX 1 AA1 SER A 1104 LEU A 1108 5 5 HELIX 2 AA2 PRO A 1112 ILE A 1116 5 5 HELIX 3 AA3 SER A 1157 PHE A 1174 1 18 HELIX 4 AA4 LEU A 1204 THR A 1211 1 8 HELIX 5 AA5 ALA A 1222 ASN A 1243 1 22 HELIX 6 AA6 ALA A 1251 ARG A 1253 5 3 HELIX 7 AA7 PHE A 1271 ARG A 1279 1 9 HELIX 8 AA8 GLY A 1287 LEU A 1291 5 5 HELIX 9 AA9 PRO A 1292 MET A 1296 5 5 HELIX 10 AB1 PRO A 1297 GLY A 1304 1 8 HELIX 11 AB2 THR A 1307 SER A 1324 1 18 HELIX 12 AB3 SER A 1334 SER A 1344 1 11 HELIX 13 AB4 PRO A 1355 TRP A 1366 1 12 HELIX 14 AB5 GLN A 1369 ARG A 1373 5 5 HELIX 15 AB6 ASN A 1375 ASP A 1389 1 15 HELIX 16 AB7 ASP A 1389 ASN A 1394 1 6 SHEET 1 AA1 2 TYR A1096 PHE A1098 0 SHEET 2 AA1 2 LYS A1101 SER A1103 -1 O SER A1103 N TYR A1096 SHEET 1 AA2 5 THR A1117 GLY A1123 0 SHEET 2 AA2 5 VAL A1130 GLN A1134 -1 O GLU A1132 N ILE A1119 SHEET 3 AA2 5 GLN A1146 THR A1151 -1 O VAL A1149 N TYR A1131 SHEET 4 AA2 5 PHE A1193 GLU A1197 -1 O LEU A1196 N ALA A1148 SHEET 5 AA2 5 CYS A1182 SER A1186 -1 N GLY A1184 O LEU A1195 SHEET 1 AA3 3 GLY A1202 ASP A1203 0 SHEET 2 AA3 3 CYS A1255 LEU A1257 -1 O LEU A1257 N GLY A1202 SHEET 3 AA3 3 ALA A1266 ILE A1268 -1 O LYS A1267 N LEU A1256 CISPEP 1 LEU A 1190 PRO A 1191 0 -3.25 CRYST1 51.602 57.389 105.432 90.00 90.00 90.00 P 21 21 21 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019379 0.000000 0.000000 0.00000 SCALE2 0.000000 0.017425 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009485 0.00000